AI Article Synopsis
Article Abstract
Background: EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC was evaluated.
Methods: This Phase 1 open-label, multicentre trial (NCT02088112) was conducted in 56 patients with NSCLC. Dose expansion permitted TKI-naive patients, primarily with activating L858R or Ex19del EGFRm. Arms 1 + 1a received concurrent therapy; Arm 2 received 4 weeks of gefitinib induction followed by concurrent therapy.
Results: From dose escalation, the recommended dose of durvalumab was 10 mg/kg Q2W with 250 mg QD gefitinib. Pharmacokinetics were as expected, consistent with inhibition of soluble PD-L1 and no treatment-emergent immunogenicity. In dose expansion, 35% of patients had elevated liver enzymes leading to drug discontinuation. In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).
Conclusions: Durvalumab and gefitinib in combination had higher toxicity than either agent alone. No significant increase in PFS was detected compared with historical controls. Therefore, concurrent PD-L1 inhibitors with gefitinib should be generally avoided in TKI-naive patients with EGFRm NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852511 | PMC |
| http://dx.doi.org/10.1038/s41416-020-01099-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer.
Ann Med Surg (Lond)
December 2024
Dow University of Health Sciences (DUHS), Karachi, Pakistan.
Nonsmall cell lung cancer (NSCLC) is the major cause of cancer-related mortality worldwide, accounting for 84% of lung cancer cases. The newly FDA-approved kinase inhibitor, repotrectinib (AUGTYRO), offers a promising option for treating advanced or metastatic NTRK/ROS1-positive Nonsmall cell lung cancer. Repotrectinib has demonstrated significant efficacy in clinical trials.
View Article and Find Full Text PDFSafety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial.
J Thorac Oncol
November 2024
Department of Clinical Research, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Centre for Cancer, Guangzhou, People's Republic of China. Electronic address:
Introduction: Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC.
View Article and Find Full Text PDFRepotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
Clin Transl Med
October 2024
Department of Medicine, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- The ROS1 proto-oncogene is linked with receptor tyrosine kinases and plays a significant role in treating ROS1 fusion-positive non-small cell lung cancer (NSCLC) using FDA-approved TKIs like crizotinib and entrectinib, though these medications face challenges such as resistance and limited brain penetration.
- Repotrectinib, a new macrocyclic TKI, was created to tackle resistance mutations and enhance brain distribution, showing strong effectiveness in the TRIDENT-1 trial with high response rates in both TKI-naïve and TKI-pretreated patients.
- The trial showed that 79% of TKI-naïve patients achieved an objective response and had longer progression
Article Synopsis
- Scientists found that using two medications together, one that stops cancer and another that helps blood vessels, can help people with a certain type of lung cancer live longer without their cancer getting worse.
- They ran a study (called the RAMOSE trial) comparing one medication plus the blood vessel helper to just the medication alone.
- The results showed that people taking both medications had better outcomes, living longer without cancer progression, even though both groups experienced side effects from the treatments.
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From and Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
J Clin Oncol
October 2024
Department of Radiation Oncology, University of Colorado, Aurora, CO.
Purpose: Newer-generation tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor () mutations and anaplastic lymphoma kinase () rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited.
Materials And Methods: Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!